It’s exciting to see software as medical device and artificial intelligence technologies moving from the early adopter phase I witnessed at FDA to the mainstream market in recent years. There’s still a lot of challenges ahead and clinical problems to solve for clinicians and patients. These tools help early-stage innovators understand where the starting line is and the commonalities and differences between various markets which is critical for decision making.